GSK vaccine for older adults granted FDA priority review
November 02, 2022 at 16:51 PM EDT
GSK reported strong third-quarter earnings and raised its forecast for 2022. However worries about Zantac litigation kept investors on edge.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|